No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Clinico-pharmacological group

Antitussive drug with bronchodilator and expectorant action

Mechanism of action

Combined drug that has mucolytic (expectorant) and antitussive effect. Butamirath, which is a part of the preparation, has a local anesthetic effect on the bronchial mucosa, which provides an antitussive effect. In addition, it has a moderate bronchodilator effect. Gvayfenezin reduces the viscosity of sputum and thereby improves its discharge.


Data on the pharmacokinetics of the drug Stoptussin not provided.

Indications for use of the drug

- dry irritating cough (including in infectious and inflammatory diseases of the upper and lower respiratory tract);

- to eliminate cough in the pre-and postoperative period (tablets).

Dosage and administration

The drug is preferably taken after meals.

Tablets should be taken without chewing, with a liquid (water, tea, fruit juice).

The appropriate number of drops is dissolved in 100 ml of liquid (water, tea, fruit juice).

The dose of the drug depends on the patient's body weight:

Body mass Dose and frequency of administration
pills oral drops
Up to 7 kg - 8 cap. 3-4 times / day
7-12 kg - 9 cap. 3-4 times / day
12-20 kg - 14 cap. 3 times / day
20-30 kg - 14 cap. 3-4 times / day
30-40 kg - 16 cap. 3-4 times / day
up to 50 kg 0.5 tab. 4 times / day 25 cap. 3 times / day
50-70 kg 1 tab. 3 times / day 30 cap. 3 times / day
70-90 kg 1.5 tab. 3 times / day 40 cap. 3 times / day
more than 90 kg 1.5 tab. 4 times / day -

The interval between doses should be 4-6 hours.

Side effect

At observance of the recommended dosing regimen, the drug is usually well tolerated.

Gastrointestinal: rarely - nausea, vomiting, diarrhea, pain in the stomach.

From the side of the central nervous system: rarely - dizziness, headache, drowsiness.

Allergic reactions: rarely - urticaria, skin rash.

Contraindications to the use of the drug

- myasthenia gravis;

- children's age up to 1 year (drops);

- children's age up to 12 years (tablets);

- I trimester of pregnancy;

- lactation period;

- hypersensitivity to the drug.

Use of the drug during pregnancy and lactation

Stoptussin should not be prescribed in the first trimester of pregnancy, for use in subsequent trimesters there must be especially important reasons.

It is not known whether butamirats are released citrate and guaifenesin with breast milk in humans. Therefore, for the use of the drug Stoptussin during lactation must be vital indications.

Special notes

During the period of drug treatment is not recommended to drink alcohol.

Influence on ability to drive motor transport and control mechanisms

The drug in high doses may have an adverse effect on activities that require increased attention, motor coordination and quick decision-making (for example, driving, car maintenance and high-altitude work).


Symptoms: signs of toxic effects of guaifenesin - drowsiness, nausea and vomiting.

Treatment: gastric lavage, reception of Activated carbon, symptomatic therapy, specific antidote of guaifenesin does not exist.

Drug interaction

The effect of guaifenesin is enhanced by lithium and Magnesium preparations.

Guaifenesin enhances the analgesic effect of Paracetamol and Acetylsalicylic acid; enhances the effect of sedatives, hypnotics and general anesthetics on the central nervous system; action of muscle relaxants, ethanol.

Terms and conditions of storage

The drug in the form of pills should be kept out of the reach of children, protected from light at a temperature not exceeding 25 ° C.

38 Items